Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy alone
Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC
It is very uncertain whether summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi… changes any severe adverse events (grade 3 or higher) (G3+ SevAE) compared with chemotherapy (very low certainty).
1 finding from 1 review
- Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes onlyRR 1.16 [0.79, 1.7]1 study · 100 participantsVery low